Publications by authors named "M Sasai"
Although direct oral anticoagulants (DOAC) have become widely used, little is known about the efficacy of DOAC for isolated distal deep vein thrombosis (DVT). In-hospitalized orthopedic patients with isolated distal DVT who were diagnosed from 2016 to 2018 were enrolled and were followed for 1 year. Embolic events included symptomatic pulmonary embolism (PE) and DVT extension above the knee.
View Article and Find Full Text PDFArticle Synopsis
- The tumor microenvironment (TME) has immune-suppressive cells, particularly T helper 1-polarized regulatory T cells (T1-T cells), but little is known about their abundance.
- Research shows that depleting arginase I-expressing tumor-associated macrophages (Arg1 TAMs) can decrease tumor growth and reduce the presence of T1-T cells.
- Arg1 TAMs produce platelet factor 4 (PF4), which promotes T1-T cell polarization via specific receptors, and targeting PF4 can limit T1-T cell accumulation and aid in fighting tumors.
Experimental autoimmune encephalomyelitis (EAE) is the most widely used rodent model for multiple sclerosis. Interferon-γ (IFN-γ) and regulatory T cells (Tregs) are individually well known to play beneficial roles in amelioration of EAE. However, little is known about the relationship between IFN-γ and Tregs during the disease.
View Article and Find Full Text PDFOne of the dense granule proteins named GRA15 in Toxoplasma gondii (T. gondii), is known to support an innate immune response in host through activation of NF-κB. However, little is known about advantages of GRA15 for parasites.
View Article and Find Full Text PDFArticle Synopsis
- The hemagglutinating virus of Japan envelope (HVJ-E) is an inactivated virus that has shown promise in treating chemotherapy-resistant malignant pleural mesothelioma (MPM) by inducing antitumor immunity.
- A phase I clinical study focused on determining a suitable dosage and evaluating the preliminary efficacy of HVJ-E, finding that higher doses resulted in better disease control rates compared to lower doses.
- The study concluded that HVJ-E is safe for patients and appears to have some antitumor activity, leading to plans for a phase II trial with higher dosages.